Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database

Journal of Alzheimer's Disease

Volumn 37, Issue 1, 2013, Pages 173-183

  Ito, Kaori ^a   Corrigan, Brian ^a   Romero, Klaus ^b   Anziano, Richard ^a   Neville, Jon ^b   Stephenson, Diane ^b   Lalonde, Richard ^a  

^a PFIZER INC   (United States)

^b CRITICAL PATH INSTITUTE   (United States)

Author keywords

ADAS cog; Alzheimer's disease; Coalition Against Major Diseases (CAMD); disease progression; meta analysis; placebo response

Indexed keywords

CHOLINESTERASE INHIBITOR; PLACEBO;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE DEFECT; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; HUMAN; META ANALYSIS; MINI MENTAL STATE EXAMINATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; COMPREHENSION; DATABASES, FACTUAL; HUMANS; PLACEBO EFFECT;

EID: 84883142849     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130575     Document Type: Article

References (19)

1. Enck P, Klosterhalfen S,Weimer K, Horing B, Zipfel S (2011) The placebo response in clinical trials: More questions than answers. Phil Trans R Soc B 366, 1889-1895.
2. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T, Alzheimer's disease working group (2010) Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement 6, 39-53.
3. Holford NH, Peace KE (1992) Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA 89, 11466-11470.
4. Lockwood P, EwyW, Hermann D, HolfordN(2006) Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; An example in Alzheimer's disease. Pharm Res 23, 2050-2059.
5. Wilcock G, Black S, Hendrix S, Zavitz K, Swabb E, Laughlin M on behalf of the Tarenflurbil Phase II Study investigators (2008) Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: A randomized phase II trial. Lancet Neurol 7, 483-493.
6. Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, Smith S, Borrie M, Decoteau E, DavidsonW, McDougall A, Gnarpe J, O'Donnell M, Chernesky M (2004) A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc 52, 381-387. (Pubitemid 38339518)
7. American Psychiatric Association (2000) Dementia of the Alzheimer's type. Diagnostic and statistical manual of mental disorders, fourth edition, text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC.
8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34, 939-944 (Pubitemid 14076461)
9. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D, dimebon investigators (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-tomoderate Alzheimer's disease: A randomised, double-blind, placebo-controlled study. Lancet 372, 207-215. (Pubitemid 351978110)
10. Doody R, Winblad B, Cummings J, Tariot P, Sano M, Aisen P, Selby B, Seely L (2012) Dimebon in Alzheimer's disease: Summary and contrast of three efficacy trials. Alzheimers Dement 8(4 Suppl 1), P456.
11. Romero K, de Mars M, Frank D, AnthonyM, Neville J, Kirby L, Smith K, Woosley RL (2009) The coalition against major diseases: Developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases. Clin Pharmacol Ther 86, 365-367.
12. Romero K, Corrigan B, Neville J, Kopko S, Cantillon M (2011) Striving for an integrated drug-development process for neurodegeneration: The coalition against major diseases. Neurodegener Dis Manag 1, 379-385.
13. Willavize S, Kivipelto M, Sparks D, Jones R, Breazna A, DeMicco D, Hey-Hadavi J, Schindler R, Corrigan B (2009) Disease progression of cognitive impairment in Alzheimer's disease: A model-based approach. International Conference on Alzheimer's Disease, July 11-16, Vienna, Austria, poster presentation (P1-260).
14. Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, Hey-Hadavi J, Breazna A, Schindler RJ, Ramos H; LEADe investigators (2008) The Atorvastatin/Donepezil in Alzheimer's disease study (LEADe): Design and baseline characteristics. Alzheimers Dement 4, 145-153.
15. Monsch A, Spiegel R, Berres M, Miserez A (2011) Substituting placebo in long-term trials with pre-symptomatic Alzheimer's disease patients: The placebo group simulation approach (PGSA). Alzheimers Dement 7, S785.
16. Ito K, Corrigan B, Zhao Q, French J, Miller R, Soares H, Katz E, Nicholas T, Billing B, Anziano R, Fullerton T and the Alzheimer's disease neuroimaging initiative (2011) Disease progression model for cognitive deterioration from Alzheimer's disease neuroimaging initiative database. Alzheimers Dement 7, 151-160.
17. Rogers JA, Polhamus D, Gillespie WR, Ito K, Romero K, Qiu R, Stephenson D, Gastonguay MR, Corrigan B (2012) Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: A beta regression metaanalysis. J Pharmacokinet Pharmacodyn 39, 479-498.
18. Samtani MN, Farnum M, Lobanov V, Yang E, Raghavan N, DiBernardo A, Narayan V (2012) Alzheimer's disease neuroimaging initiative: An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative. J Clin Pharmacol 52, 629-644.
19. Williams-Faltaos D, Ying C, Wang Y, Gobburu J, Zhu H (2013) Quantification of disease progression and drop-out for Alzheimer's disease. Int J Clin Pharmacol Ther 51, 120-131.